Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 15,000 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the transaction, the insider directly owned 334,786 shares of the company’s stock, valued at $7,017,114.56. The trade was a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00.
• On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.27, for a total transaction of $304,050.00.
• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.60, for a total transaction of $384,000.00.

Kestra Medical Technologies Stock Performance

Shares of KMTS traded down $0.23 during mid-day trading on Monday, hitting $19.59. 276,736 shares of the company traded hands, compared to its average volume of 323,287. The stock has a 50-day moving average price of $20.73 and a two-hundred day moving average price of $23.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -4.95 and a beta of 0.82. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The business had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. Kestra Medical Technologies’s revenue for the quarter was up 62.7% compared to the same quarter last year. Equities analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on KMTS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. The Goldman Sachs Group cut their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, BTIG Research restated a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $27.40.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies in the fourth quarter worth approximately $31,000. Russell Investments Group Ltd. boosted its position in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Kestra Medical Technologies in the third quarter worth approximately $48,000. BNP Paribas Financial Markets boosted its position in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the period. Finally, Daiwa Securities Group Inc. bought a new position in shares of Kestra Medical Technologies in the fourth quarter worth approximately $72,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.